{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:52:37Z","timestamp":1792788757219,"version":"4.5.0"},"reference-count":49,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Agencia Nacional de Promoci\u00f3n Cient\u00edfica y Tecnol\u00f3gica","award":["PICT-2020 SERIE A-00978"],"award-info":[{"award-number":["PICT-2020 SERIE A-00978"]}],"id":[{"id":"https:\/\/ror.org\/03stxzb56","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Agencia Nacional de Promoci\u00f3n Cient\u00edfica y Tecnol\u00f3gica","award":["PICT-2020 SERIE A-00882"],"award-info":[{"award-number":["PICT-2020 SERIE A-00882"]}],"id":[{"id":"https:\/\/ror.org\/03stxzb56","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Consejo Nacional de Investigaciones Cient\u00edficas y Tecnol\u00f3gicas","award":["PIP 2021-2023. N\u00ba 1220200100370CO"],"award-info":[{"award-number":["PIP 2021-2023. N\u00ba 1220200100370CO"]}],"id":[{"id":"https:\/\/ror.org\/03cqe8w59","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>\n                    Immunotherapy has introduced a new era in cancer treatment. The clinical goal of cancer immunotherapy is to prime the host immune system to provide passive or active immunity against malignant tumors. We have previously demonstrated that\n                    <jats:italic>Brucella abortus<\/jats:italic>\n                    (\n                    <jats:italic>Ba<\/jats:italic>\n                    ) RNA downregulates IFN-\u03b3-induced MHC-I surface expression in human monocytes\/macrophages via a TLR8-dependent mechanism. Other bacterial RNAs can mimic this phenomenon. The presence and activity of NK cells in tumors have been correlated with better patient survival, supporting the evidence that these cells are essential in the immune response against tumors. So, we postulated that bacterial RNA (bacRNA) can be used to modulate MHC-I expression in tumors to enhance the NK cell response. Hence, the aim of this study was to investigate the immunomodulatory role of bacRNA in solid tumors. We first stimulated human glioblastomas U251 and LN-229, colorectal adenocarcinoma HT-29, breast cancer MCF-7, and murine melanoma B16-OVA cells with bacRNA in the presence of IFN-\u03b3. Our experiments demonstrated that bacRNA diminished IFN-\u03b3-induced MHC-I surface expression in all tumor cell lines. Moreover, the hTLR8 agonist ORN06\/LyoVec mimicked the effect of bacRNA, indicating that MHC-I reduction would be mediated by TLR8. In addition, the decrease in MHC-I mediated by bacRNA correlated with increased NK cytotoxicity. Finally, treatment with either bacRNA or the ORN06 agonist resulted in greater immune cell infiltration and activation within the tumor compared to untreated mice. Furthermore, bacRNA delayed tumor growth in the B16 melanoma model. Overall, our established model of MHC-I downregulation (either by bacRNA or synthetic hTLR8 agonists) could be used as a therapeutic strategy to promote anti-tumor responses.\n                  <\/jats:p>","DOI":"10.1371\/journal.pone.0357999","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T18:06:28Z","timestamp":1789495588000},"page":"e0357999","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bacterial RNA downregulates MHC-I in tumor cell lines, promoting NK response and delaying tumor growth"],"prefix":"10.1371","volume":"21","author":[{"given":"Agustina","family":"Serafino","sequence":"first","affiliation":[{"name":"Instituto de Medicina Experimental-Consejo Nacional de Investigaciones Cient\u00edficas y T\u00e9cnicas (CONICET), Academia Nacional de Medicina","place":["Buenos Aires, Argentina"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f3nica","family":"Vermeulen","sequence":"additional","affiliation":[{"name":"Instituto de Medicina Experimental-Consejo Nacional de Investigaciones Cient\u00edficas y T\u00e9cnicas (CONICET), Academia Nacional de Medicina","place":["Buenos Aires, Argentina"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasm\u00edn A.","family":"Bertinat","sequence":"additional","affiliation":[{"name":"Instituto de Medicina Experimental-Consejo Nacional de Investigaciones Cient\u00edficas y T\u00e9cnicas (CONICET), Academia Nacional de Medicina","place":["Buenos Aires, Argentina"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Birnberg-Weiss","sequence":"additional","affiliation":[{"name":"Instituto de Medicina Experimental-Consejo Nacional de Investigaciones Cient\u00edficas y T\u00e9cnicas (CONICET), Academia Nacional de Medicina","place":["Buenos Aires, Argentina"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joselyn E.","family":"Castro","sequence":"additional","affiliation":[{"name":"Instituto de Medicina Experimental-Consejo Nacional de Investigaciones Cient\u00edficas y T\u00e9cnicas (CONICET), Academia Nacional de Medicina","place":["Buenos Aires, Argentina"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Bel\u00e9n","family":"Bordignon","sequence":"additional","affiliation":[{"name":"Centro de Investigaciones Oncol\u00f3gicas-Fundaci\u00f3n C\u00e1ncer F.U.C.A","place":["Buenos Aires, Argentina"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayel\u00e9n I.","family":"Pesce Viglietti","sequence":"additional","affiliation":[{"name":"Centro de Investigaciones Oncol\u00f3gicas-Fundaci\u00f3n C\u00e1ncer F.U.C.A","place":["Buenos Aires, Argentina"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorgelina","family":"Bueno","sequence":"additional","affiliation":[{"name":"Instituto de Biociencias, Biotecnolog\u00eda y Biolog\u00eda traslacional. Facultad de Ciencias Exactas y Naturales. Universidad de Buenos Aires","place":["Buenos Aires, Argentina"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7891-5169","authenticated-orcid":true,"given":"M. Ayel\u00e9n","family":"Milillo","sequence":"additional","affiliation":[{"name":"Universidad Nacional de R\u00edo Negro. Instituto de Estudios en Ciencia, Tecnolog\u00eda, Cultura y Desarrollo. Consejo Nacional de Investigaciones Cient\u00edficas y T\u00e9cnicas","place":["R\u00edo Negro, Argentina"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4940-4263","authenticated-orcid":true,"given":"Paula","family":"Barrionuevo","sequence":"additional","affiliation":[{"name":"Instituto de Medicina Experimental-Consejo Nacional de Investigaciones Cient\u00edficas y T\u00e9cnicas (CONICET), Academia Nacional de Medicina","place":["Buenos Aires, Argentina"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"key":"pone.0357999.ref001","doi-asserted-by":"crossref","first-page":"1141084","DOI":"10.3389\/fimmu.2023.1141084","article-title":"Editorial: Tumor microenvironment immunophenotypes and disease progression","volume":"14","author":"AC Monteiro","year":"2023","journal-title":"Front Immunol"},{"key":"pone.0357999.ref002","doi-asserted-by":"crossref","first-page":"713158","DOI":"10.3389\/fimmu.2021.713158","article-title":"Leveraging NKG2D Ligands in Immuno-Oncology","volume":"12","author":"MB Fuertes","year":"2021","journal-title":"Front Immunol"},{"key":"pone.0357999.ref003","doi-asserted-by":"crossref","first-page":"1212476","DOI":"10.3389\/fimmu.2023.1212476","article-title":"Cancer immunotherapies: advances and bottlenecks","volume":"14","author":"R Rui","year":"2023","journal-title":"Front Immunol"},{"issue":"1","key":"pone.0357999.ref004","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41392-023-01365-z","article-title":"Emerging phagocytosis checkpoints in cancer immunotherapy","volume":"8","author":"Y Liu","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"pone.0357999.ref005","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1158\/2159-8290.CD-20-0655","article-title":"Tumor-Infiltrating Natural Killer Cells","volume":"11","author":"B C\u00f3zar","year":"2021","journal-title":"Cancer Discov"},{"issue":"1","key":"pone.0357999.ref006","doi-asserted-by":"crossref","first-page":"13133","DOI":"10.1038\/s41598-024-62968-2","article-title":"BCG priming followed by a novel interleukin combination activates Natural Killer cells to selectively proliferate and become anti-tumour long-lived effectors","volume":"14","author":"M-J Felgueres","year":"2024","journal-title":"Sci Rep"},{"issue":"12","key":"pone.0357999.ref007","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.3390\/cancers14122923","article-title":"Microbial-Derived Toll-like Receptor Agonism in Cancer Treatment and Progression","volume":"14","author":"EF Giurini","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"3","key":"pone.0357999.ref008","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.18632\/oncotarget.6500","article-title":"The Toll-like receptor 5 agonist entolimod suppresses hepatic metastases in a murine model of ocular melanoma via an NK cell-dependent mechanism","volume":"7","author":"H Yang","year":"2016","journal-title":"Oncotarget"},{"issue":"4","key":"pone.0357999.ref009","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/cmi.12058","article-title":"Brucella abortus induces intracellular retention of MHC-I molecules in human macrophages down-modulating cytotoxic CD8(+) T cell responses","volume":"15","author":"P Barrionuevo","year":"2013","journal-title":"Cell Microbiol"},{"key":"pone.0357999.ref010","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.micinf.2018.12.004","article-title":"Inhibition of antigen presentation by Brucella: many more than many ways","volume":"21","author":"P Barrionuevo","year":"2019","journal-title":"Microbes Infect"},{"key":"pone.0357999.ref011","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.coi.2018.09.018","article-title":"Dead or alive: how the immune system detects microbial viability","volume":"56","author":"M Ugolini","year":"2019","journal-title":"Curr Opin Immunol"},{"key":"pone.0357999.ref012","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.coph.2018.05.012","article-title":"Exploiting vita-PAMPs in vaccines","volume":"41","author":"JM Blander","year":"2018","journal-title":"Curr Opin Pharmacol"},{"issue":"8","key":"pone.0357999.ref013","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006527","article-title":"B. abortus RNA is the component involved in the down-modulation of MHC-I expression on human monocytes via TLR8 and the EGFR pathway","volume":"13","author":"MA Milillo","year":"2017","journal-title":"PLoS Pathog"},{"key":"pone.0357999.ref014","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3389\/fitd.2022.924719","article-title":"Microbial RNA, the New PAMP of Many Faces","volume":"3","author":"MA Milillo","year":"2022","journal-title":"Frontiers in Tropical Diseases"},{"issue":"7","key":"pone.0357999.ref015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0306429","article-title":"Beyond its preferential niche: Brucella abortus RNA down-modulates the IFN-\u03b3-induced MHC-I expression in epithelial and endothelial cells","volume":"19","author":"A Serafino","year":"2024","journal-title":"PLoS One"},{"issue":"1","key":"pone.0357999.ref016","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1042\/BCJ20160876","article-title":"Kinetic and thermodynamic studies of the interaction between activating and inhibitory Ly49 natural killer receptors and MHC class I molecules","volume":"474","author":"PN Romasanta","year":"2017","journal-title":"Biochem J"},{"issue":"10","key":"pone.0357999.ref017","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.1128\/iai.63.10.4029-4033.1995","article-title":"Lack of a role for natural killer cells in early control of Brucella abortus 2308 infections in mice","volume":"63","author":"DM Fernandes","year":"1995","journal-title":"Infect Immun"},{"key":"pone.0357999.ref018","doi-asserted-by":"crossref","first-page":"127082","DOI":"10.1016\/j.micres.2022.127082","article-title":"Bacteria and tumor: Understanding the roles of bacteria in tumor genesis and immunology","volume":"261","author":"M Zhao","year":"2022","journal-title":"Microbiol Res"},{"issue":"2","key":"pone.0357999.ref019","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3390\/vaccines8020329","article-title":"Modulation of Anti-Tumour Immune Responses by Probiotic Bacteria","volume":"8","author":"G Aindelis","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"pone.0357999.ref020","doi-asserted-by":"crossref","first-page":"1273254","DOI":"10.3389\/fcimb.2023.1273254","article-title":"The crosstalk of intratumor bacteria and the tumor","volume":"13","author":"J Huang","year":"2024","journal-title":"Front Cell Infect Microbiol"},{"issue":"1","key":"pone.0357999.ref021","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/BF00199464","article-title":"Antitumor activity of living or killed Brucella: modification of the non-specific cytotoxic effector cells","volume":"15","author":"L Dazord","year":"1983","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"pone.0357999.ref022","doi-asserted-by":"crossref","first-page":"2160094","DOI":"10.1080\/2162402X.2022.2160094","article-title":"BCG-activation of leukocytes is sufficient for the generation of donor-independent innate anti-tumor NK and \u03b3\u03b4 T-cells that can be further expanded in vitro","volume":"12","author":"G Esteso","year":"2022","journal-title":"Oncoimmunology"},{"issue":"1","key":"pone.0357999.ref023","doi-asserted-by":"crossref","first-page":"2104991","DOI":"10.1080\/2162402X.2022.2104991","article-title":"The MICA-NKG2D axis in clear cell renal cell carcinoma bolsters MICA as target in immuno-oncology","volume":"11","author":"F Secchiari","year":"2022","journal-title":"Oncoimmunology"},{"issue":"5","key":"pone.0357999.ref024","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s13238-020-00813-8","article-title":"Unexpected guests in the tumor microenvironment: microbiome in cancer","volume":"12","author":"A Wong-Rolle","year":"2021","journal-title":"Protein Cell"},{"issue":"3","key":"pone.0357999.ref025","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s12029-019-00311-z","article-title":"Microbiome Dysbiosis and Predominant Bacterial Species as Human Cancer Biomarkers","volume":"51","author":"MSR Shirazi","year":"2020","journal-title":"J Gastrointest Cancer"},{"issue":"21","key":"pone.0357999.ref026","doi-asserted-by":"crossref","first-page":"7914","DOI":"10.3390\/ijms21217914","article-title":"Bacteria Residing at Root Canals Can Induce Cell Proliferation and Alter the Mechanical Properties of Gingival and Cancer Cells","volume":"21","author":"\u0141 Suprewicz","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"1","key":"pone.0357999.ref027","doi-asserted-by":"crossref","first-page":"5321","DOI":"10.1038\/s41598-020-62139-z","article-title":"Colorectal cancer-associated anaerobic bacteria proliferate in tumor spheroids and alter the microenvironment","volume":"10","author":"SH Kasper","year":"2020","journal-title":"Sci Rep"},{"issue":"1","key":"pone.0357999.ref028","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13046-021-01845-6","article-title":"Gut microbiota influence tumor development and Alter interactions with the human immune system","volume":"40","author":"Y Ge","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"pone.0357999.ref029","doi-asserted-by":"crossref","first-page":"533","DOI":"10.3389\/fimmu.2019.00533","article-title":"Regulatory T Cells and Plasmacytoid Dendritic Cells Within the Tumor Microenvironment in Gastric Cancer Are Correlated With Gastric Microbiota Dysbiosis: A Preliminary Study","volume":"10","author":"Z Ling","year":"2019","journal-title":"Front Immunol"},{"issue":"5","key":"pone.0357999.ref030","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/nrc.2017.13","article-title":"Microbiota: a key orchestrator of cancer therapy","volume":"17","author":"S Roy","year":"2017","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"pone.0357999.ref031","doi-asserted-by":"crossref","DOI":"10.1016\/j.chom.2023.01.013","article-title":"Tissue-resident Lachnospiraceae family bacteria protect against colorectal carcinogenesis by promoting tumor immune surveillance","volume":"31","author":"X Zhang","year":"2023","journal-title":"Cell Host Microbe"},{"key":"pone.0357999.ref032","doi-asserted-by":"crossref","first-page":"118296","DOI":"10.1016\/j.lfs.2020.118296","article-title":"Obligate and facultative anaerobic bacteria in targeted cancer therapy: Current strategies and clinical applications","volume":"261","author":"M Dr\u00f3\u017cd\u017c","year":"2020","journal-title":"Life Sci"},{"issue":"3","key":"pone.0357999.ref033","first-page":"261","article-title":"Recent advances in cancer immunotherapy: Modulation of tumor microenvironment by Toll-like receptor ligands","volume":"12","author":"L Rostamizadeh","year":"2022","journal-title":"Bioimpacts"},{"key":"pone.0357999.ref034","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/978-1-4939-6445-1_2","article-title":"Development of the CpG Adjuvant 1018: A Case Study","volume":"1494","author":"JD Campbell","year":"2017","journal-title":"Methods Mol Biol"},{"key":"pone.0357999.ref035","doi-asserted-by":"crossref","first-page":"127252","DOI":"10.1016\/j.ijbiomac.2023.127252","article-title":"Revolutionizing medicine with toll-like receptors: A path to strengthening cellular immunity","volume":"253","author":"JA Malik","year":"2023","journal-title":"Int J Biol Macromol"},{"issue":"6","key":"pone.0357999.ref036","doi-asserted-by":"crossref","first-page":"185","DOI":"10.4049\/immunohorizons.1700063","article-title":"Recent Advances in the Discovery and Delivery of TLR7\/8 Agonists as Vaccine Adjuvants","volume":"2","author":"DJ Dowling","year":"2018","journal-title":"Immunohorizons"},{"issue":"36","key":"pone.0357999.ref037","doi-asserted-by":"crossref","first-page":"4304","DOI":"10.1016\/j.vaccine.2016.06.080","article-title":"Evaluation of novel synthetic TLR7\/8 agonists as vaccine adjuvants","volume":"34","author":"AJ Smith","year":"2016","journal-title":"Vaccine"},{"issue":"4","key":"pone.0357999.ref038","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41590-018-0068-4","article-title":"Recognition of microbial viability via TLR8 drives TFH cell differentiation and vaccine responses","volume":"19","author":"M Ugolini","year":"2018","journal-title":"Nat Immunol"},{"key":"pone.0357999.ref039","doi-asserted-by":"crossref","first-page":"198","DOI":"10.3389\/fimmu.2019.00198","article-title":"Crucial Role of Nucleic Acid Sensing via Endosomal Toll-Like Receptors for the Defense of Streptococcus pyogenes in vitro and in vivo","volume":"10","author":"A Hafner","year":"2019","journal-title":"Front Immunol"},{"issue":"1","key":"pone.0357999.ref040","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.immuni.2020.06.014","article-title":"Immune Sensing Mechanisms that Discriminate Self from Altered Self and Foreign Nucleic Acids","volume":"53","author":"E Bartok","year":"2020","journal-title":"Immunity"},{"issue":"7","key":"pone.0357999.ref041","article-title":"Toll-like receptor 7\/8 agonist R848 alters the immune tumor microenvironment and enhances SBRT-induced antitumor efficacy in murine models of pancreatic cancer","volume":"10","author":"J Ye","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"15","key":"pone.0357999.ref042","doi-asserted-by":"crossref","first-page":"24932","DOI":"10.18632\/oncotarget.15326","article-title":"The TLR7 agonist imiquimod induces anti-cancer effects via autophagic cell death and enhances anti-tumoral and systemic immunity during radiotherapy for melanoma","volume":"8","author":"JH Cho","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"pone.0357999.ref043","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3892\/ijo.2022.5371","article-title":"The TLR7\/8 agonist R848 optimizes host and tumor immunity to improve therapeutic efficacy in murine lung cancer","volume":"61","author":"J Zhou","year":"2022","journal-title":"Int J Oncol"},{"issue":"1","key":"pone.0357999.ref044","doi-asserted-by":"crossref","first-page":"4682","DOI":"10.1038\/s41467-019-12657-w","article-title":"The TLR7\/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer","volume":"10","author":"KA Michaelis","year":"2019","journal-title":"Nat Commun"},{"issue":"1","key":"pone.0357999.ref045","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1186\/s12951-024-02525-1","article-title":"A combination of a TLR7\/8 agonist and an epigenetic inhibitor suppresses triple-negative breast cancer through triggering anti-tumor immune","volume":"22","author":"Z Jiang","year":"2024","journal-title":"J Nanobiotechnology"},{"issue":"6","key":"pone.0357999.ref046","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1021\/acs.molpharmaceut.0c00271","article-title":"TLR7\/8 Agonist-Loaded Nanoparticles Augment NK Cell-Mediated Antibody-Based Cancer Immunotherapy","volume":"17","author":"H Kim","year":"2020","journal-title":"Mol Pharm"},{"issue":"8","key":"pone.0357999.ref047","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/s41551-018-0236-8","article-title":"TLR7\/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy","volume":"2","author":"CB Rodell","year":"2018","journal-title":"Nat Biomed Eng"},{"key":"pone.0357999.ref048","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1042\/BST0351485","article-title":"Immunostimulatory activity of Toll-like receptor 8 agonists towards human leucocytes: basic mechanisms and translational opportunities","volume":"35","author":"VJ Philbin","year":"2007","journal-title":"Biochem Soc Trans"},{"issue":"2","key":"pone.0357999.ref049","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0148764","article-title":"Coordinated Activation of Toll-Like Receptor8 (TLR8) and NLRP3 by the TLR8 Agonist, VTX-2337, Ignites Tumoricidal Natural Killer Cell Activity","volume":"11","author":"GN Dietsch","year":"2016","journal-title":"PLoS One"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0357999","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T18:06:35Z","timestamp":1789495595000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0357999"}},"subtitle":[],"editor":[{"given":"Sriram","family":"Chitta","sequence":"first","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center","place":["UNITED STATES OF AMERICA"]}],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":49,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9,15]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0357999","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]}}}